EUVIMEDEUVIMED entdecken
Crossref

Performance of the BD Phoenix CPO detect assay for the detection and classification of OXA-48 producing-Escherichia coli that do not co-produce ESBL/pAmpC

Fátima Galán-Sánchez, Inés Portillo-Calderón, Manuel Rodriguez-Iglesias, Álvaro Pascual, Lorena López-Cerero

Enfermedades infecciosas y microbiologia clinica (English ed.) · 2026

DOI: 10.1016/j.eimce.2025.503035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2026. Verfasst von Fátima Galán-Sánchez und 4 weiteren Autor:innen. Beteiligte Einrichtung: UGC Microbiología, Hospital Universitario Puerta del Mar, Cádiz, Spain; Instituto de Investigación e Innovación Biomédica de Cádiz (INIBICA), Hospita…. Hauptthemen laut MEDLINE: beta-Lactamases, Escherichia coli, Bacterial Proteins, Escherichia coli Proteins. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The BD Phoenix™ Emerge panel incorporates the CPO detect test (CPO-T), which enables both detection and classification of carbapenemases. Integrating reliable carbapenemase detection - particularly group D enzymes - into routine antimicrobial susceptibility testing (AST), along with rapid susceptibility results, supports early optimization of antimicrobial therapy and implementation of infection control measures. These actions are essential for improving clinical outcomes and limiting the spread of resistance. This study evaluated the performance of CPO-T in detecting carbapenemase activity in a well-characterized collection of Escherichia coli isolates producing only OXA-48, without co-production of ESBL or pAmpC (OXA48-NoE-NoA-E. coli). Additionally, we assessed the BD Phoenix™ system ability to provide rapid antimicrobial susceptibility results. METHODS: Fifty-one OXA48-NoE-NoA-E. coli isolates were included. Ten carbapenem-resistant, non-carbapenemase-producing isolates served as negative controls (NC). All isolates underwent whole-genome sequencing using Illumina technology, and carbapenem MICs were determined by reference broth microdilution. RESULTS: CPO-T detected carbapenemase activity in 100% of the OXA48-NoE-NoA-E. coli isolates, with 82.4% correctly assigned to Ambler class D. Three NC isolates were misclassified as carbapenemase producers. The BD Phoenix™ system provided definitive susceptibility results in under 8h for 64.6% of the antibiotics tested. CONCLUSIONS: CPO-T is a reliable tool for detecting OXA48-NoE-NoA-E. coli, even in phenotypically complex cases. To ensure rapid and accurate classification, a confirmatory test - such as immunochromatography - should be performed. The BD Phoenix™ system also enables timely AST, supporting early and informed therapeutic decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-LactamasesEscherichia coliBacterial ProteinsEscherichia coli ProteinsMicrobial Sensitivity TestsHumansAnti-Bacterial Agents

Stichwörter der Autor:innen

BD PhoenixCPO detect testEscherichia coliOXA-48Panel CPO test

Substanzen

beta-LactamasesBacterial Proteinsbeta-lactamase OXA-48, E coliEscherichia coli ProteinscarbapenemaseAnti-Bacterial Agents

Autor:innen und Institutionen

  • UGC Microbiología, Hospital Universitario Puerta del Mar, Cádiz, Spain; Instituto de Investigación e Innovación Biomédica de Cádiz (INIBICA), Hospital Universitario Puerta del Mar, Cádiz, Spain. Electronic address: fati…
  • UGC de Enfermedades Infecciosas y Microbiología Clínica, Hospital Universitario Virgen Macarena, Sevilla, Spain; Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen Macarena/CSIC/Universidad de Sevilla, S…
  • UGC Microbiología, Hospital Universitario Puerta del Mar, Cádiz, Spain; Instituto de Investigación e Innovación Biomédica de Cádiz (INIBICA), Hospital Universitario Puerta del Mar, Cádiz, Spain; Departamento de Biomedic…

Zitieren

APA

Galán-Sánchez, F., Portillo-Calderón, I., Rodriguez-Iglesias, M., Pascual, Á., & López-Cerero, L. (2026). Performance of the BD Phoenix CPO detect assay for the detection and classification of OXA-48 producing-Escherichia coli that do not co-produce ESBL/pAmpC. Enfermedades infecciosas y microbiologia clinica (English ed.). https://doi.org/10.1016/j.eimce.2025.503035

Vancouver

Galán-Sánchez F, Portillo-Calderón I, Rodriguez-Iglesias M, Pascual Á, López-Cerero L. Performance of the BD Phoenix CPO detect assay for the detection and classification of OXA-48 producing-Escherichia coli that do not co-produce ESBL/pAmpC. Enfermedades infecciosas y microbiologia clinica (English ed.). 2026. doi:10.1016/j.eimce.2025.503035

BibTeX
@article{GalnSnchez2026,
  author = {Galán-Sánchez, Fátima and Portillo-Calderón, Inés and Rodriguez-Iglesias, Manuel and Pascual, Álvaro and López-Cerero, Lorena},
  title = {Performance of the BD Phoenix CPO detect assay for the detection and classification of OXA-48 producing-Escherichia coli that do not co-produce ESBL/pAmpC},
  journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
  year = {2026},
  doi = {10.1016/j.eimce.2025.503035}
}
Kostenlos starten →